The pattern of activation of CD3+CD56+CD8+ cells was quite similar to that reported by our group and others for Treg, which have a peak during the second and third trimesters and declining at PP (35), which could reflect their possible implication in MS activity during pregnancy and PP. The gene discussed is CD8A; the disease is myeloid sarcoma.